Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma
- PDF / 560,183 Bytes
- 5 Pages / 595.276 x 790.866 pts Page_size
- 8 Downloads / 272 Views
CASE REPORT
Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma Tomoko Adachi1 · Atsushi Hiraoka1 · Hidenori Okazaki2 · Kensuke Nagamatsu1 · Hirofumi Izumoto1 · Takeaki Yoshino1 · Miho Tsuruta1 · Toshihiko Aibiki1 · Tomonari Okudaira1 · Hiroka Yamago1 · Ryuichiro Iwasaki1 · Yoshifumi Suga1 · Kenichiro Mori1 · Hideki Miyata1 · Eiji Tsubouchi1 · Tomoyuki Ninomiya1 · Kojiro Michitaka1 Received: 20 December 2019 / Accepted: 21 May 2020 © Japanese Society of Gastroenterology 2020
Abstract We treated a 66-year-old Japanese male with unresectable hepatocellular carcinoma (u-HCC) for multiple (>5) liver tumors (maximum 2.6 cm in size, Child–Pugh B score 7) in September 2018. The patient had a history of psoriasis vulgaris and sorafenib (SOR) was introduced (800 mg/day) because of transcatheter arterial chemoembolization (TACE) refractoriness. However, psoriasis vulgaris exacerbation and a high fever were observed 2 weeks later, and the patient was admitted, after which improvement of psoriasis vulgaris was obtained with external medicine administration and SOR intake discontinuation. Few reports have noted exacerbation of psoriasis vulgaris caused by SOR treatment. Keywords Hepatocellular carcinoma · Psoriasis vulgaris · Sorafenib
Introduction Sorafenib (SOR) has been shown to have an important role for improving the prognosis of patients with unresectable hepatocellular carcinoma (u-HCC) [1], and the idea of
transcatheter arterial chemoembolization (TACE) refractory [2] has been proposed to switch to SOR without deterioration of hepatic reserve function. It has been reported that switching to SOR prolonged the period to liver failure and to appearance of extrahepatic metastasis [3], and improving
* Atsushi Hiraoka [email protected]‑u.ac.jp
Ryuichiro Iwasaki [email protected]
Tomoko Adachi [email protected]
Yoshifumi Suga [email protected]
Hidenori Okazaki [email protected]
Kenichiro Mori [email protected]
Kensuke Nagamatsu [email protected]
Hideki Miyata [email protected]
Hirofumi Izumoto [email protected]
Eiji Tsubouchi [email protected]
Takeaki Yoshino [email protected]
Tomoyuki Ninomiya [email protected]‑ho.ne.jp
Miho Tsuruta [email protected]
Kojiro Michitaka [email protected]
Toshihiko Aibiki [email protected]
1
Gastroenterology Center, Ehime Prefectural Central Hospital, 83 Kasuga‑cho, Matsuyama, Ehime 790‑0024, Japan
2
Department of Dermatology, Ehime Prefectural Central Hospital, Matsuyama, Japan
Tomonari Okudaira [email protected] Hiroka Yamago [email protected]
13
Vol.:(0123456789)
Clinical Journal of Gastroenterology
survival period [4]. Clinical efficacy of switching to SOR from TACE has been recognized and number of treatment with SOR also has been increasing, and hand–foot skin reaction is known as the most frequent adverse event of skin in SOR treatment [1, 5]. However, few studies have examined exacerbation of psoriasis vulg
Data Loading...
